United States· US:73116-215_30ff13f0-1e77-43de-99c9-c309834f1e63
COPIKTRA
A duvelisib product containing duvelisib, registered in United States by Secura Bio, Inc. The same ATC class is registered in 6 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Duvelisib is registered in 6 of 19 countries.
Countries holding a registration under ATC L01EM04 (duvelisib), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 4 of them publish a price we can compare per daily dose
Duvelisib · ATC L01EM04
6 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DUVELISIB
- Manufacturer
- Secura Bio, Inc
- Country
- United States (US)
- ATC code
- L01EM04
- ATC class
- Duvelisib
- Defined daily dose
- 50 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc1173116-215-28
- ndc1173116-215-56
- ndc11731162152828 CAPSULE in 1 PACKAGE (73116-215-28)
- ndc11731162155656 CAPSULE in 1 PACKAGE (73116-215-56)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
313 interactions on record for duvelisib.
Graded by severity as the source publishes them — 71 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Duvelisib · interactions on record
313 records
- 71 severe
- 234 moderate
- 8 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- CilostazolB01AC23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Duvelisib in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/786a09a4-b3dc-492b-9e7d-d810ce1ad3c0 GET /v1/drugs/786a09a4-b3dc-492b-9e7d-d810ce1ad3c0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "15",
"substance": "DUVELISIB",
"productndc": "73116-215",
"dosage_form": "CAPSULE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA211155",
"marketing_category": "NDA"
}See everything about duvelisib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.